Granulysin is a cytolytic molecule with perforin and granzymes that is expressed by activated human CTLs, NK and γδ T cells, and it has broad antimicrobial activity, including to drug-sensitive and drug-resistant Mycobacterium tuberculosis. We hypothesized that approaches facilitating the expression of granulysin in M. tuberculosis-infected host cells in the lung may provide a novel treatment strategy for pulmonary TB. In this study, a recombinant replication-deficient adenovirus serotype 5-based rAdhGLi was constructed that expressed human granulysin in the cytosol of the U937 and RAW264.7 macrophage-like cell lines as confirmed by western blotting and co-localization technology using indirect immunofluorescence staining. Ninety-six hours after both cell lines were infected with M. tuberculosis, acid-fast staining and enumeration demonstrated that rAdhGLi-treated cells had a lower colonyforming units (CFU) of intracellular bacteria than culture medium or AdNull controls. Granulysin was only expressed in the lung and not in other organs following inhalation of rAdhGLi. In particular, immunocompetent BALB/c mice or SCID mice intranasally infected with~200 CFU of virulent M. tuberculosis H37Rv intranasally were treated with rAdhGLi, and they showed decreased bacterial loads in the lung when compared with phosphate-buffered saline or AdNull controls. Importantly, a clear dose-dependent rAdhGLi treatment efficacy was found in infected BALB/c mice, with the most significant reduction in lung bacteria obtained in BALB/c mice treated with 10 9 plaque-forming units of rAdhGLi without any pathological changes. Our study indicates that rAdhGLi may be used as a novel and efficient treatment strategy with the capability to directly kill intracellular M. tuberculosis.
INTRODUCTION
Although chemotherapy and Bacillus Calmette-Guerin (BCG) vaccines have been available for the treatment and prevention of tuberculosis (TB), TB remains a leading infectious disease worldwide, with~9 million new cases and 1.5 million deaths each year. 1 Moreover, the WHO estimated in 2013 that~3.5% new cases and 20.5% of previously treated cases have multidrugresistant TB,~9% of which were extensively drug-resistant TB, which was reported in 13 countries in 2007 and 100 countries in 2013. 1 The standard strategy of a 6-month treatment with first-line anti-TB drugs is not suitable for treating drug-resistant TB disease, which requires at least 2 years of treatment with less active, more toxic and expensive drugs with poor success rates. 2 This serious situation is further exacerbated by co-infection with HIV, a lethal combination 1-3 that calls for urgent development of new drugs and treatment strategies.
Activated human CTLs, NK and γδ T cells have the potential to eliminate intracellular pathogens such as bacteria or viruses by inducing the death of infected cells. [4] [5] [6] The process involves the release of cytolytic granules containing perforin and granzymes, which are expressed by these cells in all mammals, and granulysin, which is expressed in humans and some mammals, but not mice. The role of perforin is to generate a pore on the cell membrane and allow other cytolytic molecules into the cytosol. Subsequently, granulysin, which belongs to the family of saposin-like lipid proteins, is toxic to a variety of intracellular microbes, [4] [5] [6] including M. tuberculosis, by damaging the cell wall and disrupting the lipid metabolism of M. tuberculosis to generate osmotic shock. 4 Granulysin is also able to generate pores on the surface of bacteria, promoting infiltration of the granzymes into the bacterial cytosol and killing various bacteria via the generation of radical oxygen species. 7 In particular, synthetic peptides based on granulysin also exhibit better inhibition activity to single drugresistant and even multidrug-resistant TB strains in vitro, 8 and in transgenic mice that constitutively express human granulysin, there is significantly inhibition of the growth of M. tuberculosis in infected mice. 9 However, to kill intracellular M. tuberculosis, granulysin depends on the effect of perforin to cross the cell membrane of host cells. 4 Despite the availability of purified granulysin from genetically engineered Escherichia coli 4 or yeast, 10 the ability of active granulysin to reach the lung is still a significant barrier for its use in possible TB treatment.
We hypothesize that approaches facilitating the expression of granulysin in M. tuberculosis-infected host cells in the lung tissue may provide a novel treatment strategy for pulmonary TB, as evidenced by the lysis of intracellular listeria. 11 Replicationdeficient (E1-deleted) adenovirus vectors are particularly suitable for the expression of specific gene products in the lung and have proven effective as promising vaccine candidates for protection against a variety of different infectious diseases, 12 including TB, 13, 14 and as a gene therapy against tumors. 15 In this study, a novel recombinant adenovirus vector expressing intracellular granulysin (rAdhGLi) was constructed. The effects of rAdhGLi on the activity of cells in vitro and on intracellular M. tuberculosis ex vivo were analyzed. Moreover, the treatment efficacy of rAdhGLi inhalation in BALB/c mice and SCID mice infected with virulent M. tuberculosis H37Rv was also evaluated.
RESULTS

Intracellular expression of granulysin in rAdhGLi-treated macrophages
The gene fragment encoding the 238 bp human granulysin with the start code ATG was digested from the pUChGLi plasmid with EcoRI and HindIII and subcloned into the corresponding sites of the adenoviral vector pDC316. This resulted in the recombinant shuttle plasmid pDChGLi that was further confirmed by DNA sequencing and enzymatic digestion. As shown in Figure 1a , the recombinant replication-deficient adenovirus serotype 5 rAdhGLi was constructed, packaged and purified from human embryonic kidney 293 cells. The genome structure of rAdhGLi is described in Figure 1a , and it was designed to express intracellular granulysin under the IE promoter of MCMV.
To confirm the expression and location of granulysin in macrophages, both U937 and RAW264.7 cells, which have the morphology and characteristics of mature macrophages, were used. The expression of granulysin in both the supernatants and lysates of rAdhGLi-treated cells was detected by western blotting at 72 h post treatment. As shown in Figure 1b , recombinant granulysin with a size of~8.8 kDa was only present in the lysates and not in the supernatants (data not shown) of both cells. As expected, no specific expression of granulysin was observed in AdNull-infected cells ( Figure 1b ).
Qualitative evaluation was also performed by using indirect immunofluorescence staining and co-localization technology. As shown in Figure 2 , a few U937 and RAW264.7 cells expressed granulysin in the cytosol 48 h after treatment with rAdhGLi. However, 72 h later, intracellular granulysin was expressed by many more cells, and the expression levels were also significantly increased ( Figure 2 ).
No obvious changes in the proliferation and death of rAdhGLitreated macrophages Because granulysin, perforin and granzymes as cytolytic granules are expressed by activated human CTL cells and result in the death of pathogen-infected cells, the effects of rAdhGLi on the proliferation and death of macrophages were evaluated. As shown in Figure 3a , the proliferation of rAdhGLi-treated, AdNull and culture medium controls of U937 or RAW264.7 cells did not show any difference in proliferation. Interestingly, only very low level of necrosis (less than 0.4%) were obtained, irrespective of treatments or different time points ( Figure 3b ). In contrast, the level of apoptosis increased over time and reached a maximum of 15% depending on the type of macrophage. However, there was no significant difference in the induction of necrosis or apoptosis among rAdhGLi-treated, AdNull and culture medium U937 or RAW264.7 groups at each time point. rAdhGLi significantly killed intracellular M. tuberculosis phagocytosed by macrophages To investigate whether rAdhGLi was able to kill intracellular M. tuberculosis, U937 cells ( Figure 4a ) and RAW264.7 cells ( Figure 4b ) were first infected with M. tuberculosis H37Rv for 24 h and then treated with rAdhGLi for another 72 h. The number of intracellular M. tuberculosis cells was counted, and AF staining was evaluated. As shown in Figure 4 , AF staining supported that both cells were successfully infected with M. tuberculosis at the respective multiplicity of infections at 24 h, and there were no residual extracellular bacteria. At 72 h after treatment, there was no significant difference in the number of colony-forming unit (CFU) between the AdNull and culture medium controls, as expected. Remarkably, the CFU of intracellular M. tuberculosis was significantly lower in the rAdhGLi-treated U937 and RAW264.7 cells than in the AdNull and culture medium controls (P o0.05). In addition, AF staining supported the results of the enumeration of CFU. Because intracellular M. tuberculosis replicated rapidly, the large amount of AF-positive intracellular bacteria aggravated and even resulted in the lysis of infected cells at 72 h after the AdNull or culture medium treatment. In contrast, some rAdhGLi-treated cells retained their complete morphology, and they may have benefited from rAdhGLi-expressed granulysin in the cytosol of cells, as the intracellular M. tuberculosis bacteria in these cells were all killed; other cells may have been damaged and disrupted by the M. tuberculosis infection, and rAdhGLi may have no obvious effects on M. tuberculosis outside of cells or in disrupted cells.
Granulysin expressed by rAdhGLi localized in the lung At 0, 24, 48, 72 h and 7 days after BALB/c mice received respiratory rAdhGLi treatment, the mice were killed, and different organs were analyzed by indirect immunofluorescence staining. As expected, no expression of granulysin in the lung of either rAdhGLi-or AdNull-treated mice was observed at the beginning of the experiment. Twenty-four hours after infection, AdNull-treated mice maintained negative expression of granulysin, whereas rAdhGLitreated mice began to express granulysin in the lung, mainly in the bronchioles ( Figure 5 ). Seventy-two hours later, the expression of granulysin increased extensively in the lung tissue of rAdhGLi-treated mice and could be detected until day 7 ( Figure 5 ). However, no clear expression of granulysin was observed in other organs of rAdhGLitreated mice (data not shown), indicating that rAdhGLi localized in the lung and did not spread to other tissues or organs. Dosage-dependent therapeutic effects of rAdhGLi on M. tuberculosis-infected immunocompetent mice BALB/c mice were infected intranasal (i.n.) with~200 CFU of M. tuberculosis. After 2 weeks, infected mice were separately treated with various doses of rAdhGLi. Four weeks later, bacterial load and pathology of the lung were evaluated. The highest bacterial load in the lung was observed in both the phosphatebuffered saline (PBS) control and AdNull-treated mice, as expected ( Figure 6 ). Bacterial load in the lung was significantly lower in mice treated with different doses of rAdhGLi than in the PBS and AdNull controls (P o0.05). Moreover, there was a clear dose-dependent relationship, with mice treated with a high dosage of rAdhGLi having the highest level of growth inhibition of M. tuberculosis in the lung compared with other groups treated with lower dosages, although there was no significant difference between the 10 8 PFU (plaque-forming unit) and 10 9 PFU rAdhGLi-treated groups. Importantly, the CFU in the lungs of mice treated with a dosage of 10 9 PFU rAdhGLi was 1000 times lower compared with the control mice. The results of bacterial enumeration in the lung were consistent with the results of AF staining in the different groups ( Figure 7 ). In addition, lung tissue sections from both control and AdNull-treated mice showed extensive and severe inflammation of the lung and alveolar destruction. Alveolar structures were well maintained with very limited and distinct inflammation for the different doses in the rAdhGLi-treated groups, especially at the high rAdhGLi dosage of 10 9 PFU (Figure 7 ).
Significant therapeutic effects of rAdhGLi on M. tuberculosisinfected SCID mice Previous granulysin-based strategies including DNA vaccination 16 and recombinant M. smegmatis strain-expressing granulysin 17 protected against TB by inducing the immune response against the expressed granulysin protein, activating APC cells, 18 and showing chemotactic activity for CD4 + and CD8 + T cells. 19 To confirm that the bactericidal effect of rAdhGLi in vivo is a direct therapeutic mechanism rather than an indirect one, SCID mice were infected with M. tuberculosis and treated with rAdhGLi. Despite the same infectious dose, SCID control mice had higher bacterial loads in the lung when compared with M. tuberculosisinfected BALB/c control mice (Figure 8 ), indicating that SCID mice could neither control the bacterial growth in the lung nor inhibit the spread to the spleen. There was no significant difference in bacterial loads between the lung and spleen between PBS-and AdNull-treated mice (Figure 8 ). Both PBS and AdNull control mice had a similar lung pathology, with limited normal lung tissue and a large amount of AF-positive bacteria clustered into groups. Notably, rAdhGLi-treated SCID mice significantly reduced the bacterial load of the lung and spleen compared with the PBS and AdNull control mice (P o0.05). Only mild inflammatory changes occurred in rAdhGLi-treated SCID mice, with less AF-positive bacteria present in the lung tissue section (Figure 8 ).
DISCUSSION
The increasing emergence of multidrug-resistant/extensively drug-resistant-TB and co-infection with HIV pose great challenges for effective TB control. 20 The problem of drug-resistant TB is partly attributed to patients' poor compliance to the lengthy 6-month chemotherapy, which can also promote the emergence of drug-resistant strains. 21 In addition, infection with HIV weakens cell-mediated immunity and results in an increasing susceptibility to infection with drug-sensitive or drug-resistant M. tuberculosis. Therefore, developing new drugs to target these forms of TB disease or shortening the treatment period is a high priority in global TB control. 20 In the present study, a recombinant replication-deficient adenovirus serotype 5-based rAdhGLi was successfully constructed, which not only effectively expresses intracellular granulysin in treated human-or murine-original macrophages but also directly kills intracellular M. tuberculosis, as evidenced by a lower CFU of intracellular bacteria ex vivo and lower bacterial loads in the lung and spleen of infected SCID mice in vivo. We demonstrated that the inhalation of high-dose rAdhGLi could significantly inhibit the growth of M. tuberculosis in the lung of infected mice with no additional damage to the lung tissue, which may provide a novel treatment strategy for TB control and for treating multidrug-resistant/extensively drug-resistant-TB.
Great progress has been made in developing novel drugs for TB over the past few decades. For example, several new drug candidates are undergoing clinical trials, 20, 22 and several are in Figure 6 . Bacterial load of the lung in BALB/c mice at 4 weeks post treatment (n = 5). Two weeks after BALB/c mice were challenged i.n. with~200 CFU virulent M. tuberculosis H37Rv strain, five mice in each group were treated once with serial infusions of rAdhGLi doses. PBS and AdNull were separately used as negative controls. Four weeks after treatment, lungs were harvested aseptically, and bacterial CFU per lung was analyzed. Results are displayed as the mean (± s.e.m.) log 10 CFU/lung. Bar represents P o0.05. Figure 7 . Representative lung histopathology of BALB/c mice after serial infusions with rAdhGLi. Two weeks after BALB/c mice were challenged i.n. with~200 CFU virulent M. tuberculosis H37Rv, five mice in each group were treated once with serial infusions of rAdhGLi. PBS and AdNull were separately used as negative controls. Four weeks after treatment, lungs were harvested aseptically, and lung histopathology was visualized by HE staining (scale bar, 400 μm) and AF staining (scale bar, 50 μm). Arrowheads indicate AF-positive bacteria.
preclinical trials, including approaches with immunotherapy 23 with mycobacterial components, 24 cytokines 25, 26 or DNA vaccination, 24, 27 antisense nucleotides 28 and siRNA. 29 However, obtaining more effective TB therapy in a shorter time still faces various challenges. 20 M. tuberculosis enters the lung via the aerosol route, where bacteria are engulfed immediately by macrophages and dendritic cells, which trigger host innate and adaptive immune responses against TB. 30 However, immune responses induced by infection with M. tuberculosis are insufficient to eliminate pathogens and promote granuloma formation in the lung. M. tuberculosis has been suspected to parasitize within macrophages in the central area of the granuloma and live dormant for most of the infected population's lifetime. 30 In an immunocompromised host, dormant M. tuberculosis reactivate and grow, resulting in pulmonary TB as the main source and disease form of adult TB. Although RIF and PZA have activity for nonreplicating M. tuberculosis, other drugs are mainly targeted toward growing bacterial populations. 21 This is a major reason why a lengthy therapy is necessary for TB treatment. Therefore, targeted killing of intracellular M. tuberculosis may be the key to solving this problem.
Granulysin has been implicated in playing an important role in anti-TB immune responses, and a granulysin/perforin-mediated pathway for CTLs responsible for protection against intracellular pathogens including M. tuberculosis has been identified. 4 It is generally accepted that protective immunity against M. tuberculosis depends on CD4 + , CD8 + , γδT cells and NK cells. 30 All of these cells are able to express granulysin and exhibit antimycobacterial activity. [4] [5] [6] 31, 32 The mechanism of immunotherapy with TB is mainly based on IFN-γ secreted by CD4 + T cells, which leads to the activation of macrophages and killing of the engulfed bacteria. 23, 27, 30 In fact, CD4 + T cells also can lyse M. tuberculosisinfected target cells with perforin and granulysin, with the latter further inhibiting mycobacterial growth. 33 In addition, CD8 + T lymphocytes at the site of infection in chronic pulmonary TB patients have an impaired expression of granulysin and perforin, 34 which contributes to the chronic process of the disease. Children with TB showed a lower level of serum granulysin than healthy controls, and no significant differences were found between both groups after successful therapy. 35 Taken together, these findings support the claim that expression of granulysin in the host may be an effective strategy for TB treatment.
In the present study, the expression of granulysin mediated by rAdhGLi-treated macrophages was only found in the cytosol of cells, as confirmed by indirect immunofluorescence staining and western blotting, as previously reported. 36 In particular, intracellular expression of granulysin by rAdhGLi significantly decreased the number of intracellular M. tuberculosis compared with the culture medium or AdNull control groups, which indicates that rAdhGLi was able to directly kill intracellular M. tuberculosis engulfed by macrophages after treatment. Approximately 40% of M. tuberculosis in the macrophage can translocate from phagosomes to the cytosol 4 h after M. tuberculosis infection 37 via the ESX-1 secretion system (T7ss). 38 This allows granulysin in the cytosol of macrophages expressed by rAdhGLi to encounter and interact with cytosol pathogens, thus resulting in the elimination of the intracellular pathogen, as demonstrated by the results of acid fast (AF) staining and enumeration of intracellular M. tuberculosis after rAdhGLi treatment. Moreover, the therapeutic effects of rAdhGLi on the infected SCID mice provide further evidence to support the direct killing mechanism of granulysin on the infected M. tuberculosis. Most importantly, treatment of M. tuberculosis-infected BALB/c mice with rAdhGLi resulted in a significant decrease in bacteria in the lung when compared with control groups, which confirms the therapeutic effects of rAdhGLi.
Wild-type adenovirus may cause mild flu symptoms in the upper airways in humans, and attenuated live adenovirus vaccines have been given mucosally to military recruits in the USA to prevent adenoviral infection. 12 Due to good safety records, low virulence, tropism to mucosal epithelial cells, easy Good Manufacturing Practice preparation and superior gene transfer efficiency, recombinant replication-deficient adenovirus systems have been widely used for gene transfer in vivo. 12,15 rAdhGLi does not cause any side effects in the treated cells, which highlights its safety. Granulysin is mainly expressed in the lung of mice after inhalation of rAdhGLi, which indicates the advantages of rAdhGLi for TB treatment.
In conclusion, our study indicates that rAdhGLi may be a novel and efficient treatment against TB with the capability to directly kill intracellular M. tuberculosis. Future studies to evaluate the effect of rAdhGLi and combination of rAdhGLi with chemotherapy Figure 8 . Therapeutic effects of rAdhGLi on SCID mice (n = 5). (a) Two weeks after SCID mice were challenged i.n. with~200 CFU virulent M. tuberculosis H37Rv, six mice in each group were treated once with PBS, 10 9 PFU of rAdhGLi or 10 9 PFU AdNull. Two weeks after treatment, lungs and spleens were harvested aseptically from mice, and bacterial CFU per organ was analyzed. Results are displayed as the mean ( ± s.e.m.) log 10 CFU/lung. Bar represents Po 0.05. (b) Lung histopathology of SCID mice after treatment with 10 9 PFU of rAdhGLi was visualized by hematoxylin and eosin (scale bar, 400 μm) and AF staining (scale bar, 50 μm). Arrowheads indicate AF-positive bacteria.
to shorten the treatment of drug susceptibility and drug-resistant TB are warranted.
MATERIALS AND METHODS
Construction of recombinant replication-deficient adenovirus serotype 5-based rAdhGLi
The cDNA of granulysin encoding human granulysin was synthesized and cloned into the pUChGLi vector (Sangon Biotech, Shanghai, China). The plasmid pUChGLi was digested with EcoR I and HindIII, and the gene fragment of 238 bp was then recovered and subcloned into corresponding restriction sites of pDC316 (Microbix, Mississauga, ON, Canada) to result in the recombinant plasmid pDChGLi. The correctness of pDChGLi was confirmed by enzyme digestion and DNA sequencing. pDChGLi and rescuing vector pBHGloxΔE1, 3Cre (Microbix) plasmids for recombinant adenovirus packaging were transformed into the competent E. coli DH5α strain. Endotoxin-free plasmids were purified using the Qiagen Plasmid Giga kit (Qiagen, Shanghai, China). Human embryonic kidney 293 cells grown in 10% fetal bovine serum-Dulbecco's modified Eagle's medium (Hyclone, Logan, UT, USA) were co-transfected with pDChGLi and pBHGloxΔE1,3Cre (1:1) using Lipofactamine 2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions. Recombinant replication-deficient adenovirus rAdhGLi was rescued by homologous recombination, amplified in human embryonic kidney 293 cells, and purified with the standard method of CsCl density gradient centrifugation. The purified recombinant adenovirus rAdhGLi was first dialyzed against sterilized Tris-HCl solution (50 g sucrose, 10 ml of 1 M Tris-HCl pH 8.0 and 2 ml of 1 M MgCl 2 l − 1 ) for 24 h at 4°C, then aliquoted, and stored at − 80°C for further assays. The titer for recombinant adenovirus rAdhGLi was determined using the Adenovirus Rapid Titer Testing kit (Neuron Biotech., Shanghai, China), and the results are displayed as PFU ml − 1 .
Expression of granulysin in rAdhGLi-treated U937 and RAW264.7 cells Both U937 cells (human histiocytic lymphoma cell line) and RAW264.7 cells (mouse leukemic monocyte macrophage cell line) were provided by the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were plated at a density of 1 × 10 6 cells per well in six-well plates and maintained in 2 ml of RPMI 1640 medium (Hyclone) or Dulbecco's modified Eagle's medium medium supplemented with 10% fetal bovine serum. For observations, cells were separately treated with rAdhGLi at a multiplicity of infections of 2000:1 and 300:1 (PFU of rAdhGLi virus:cells), based on the results of the pilot study. Wild-type adenovirus serotype 5 AdNull (Obio Tech.) infected cells were used as a negative control.
To confirm the expression and location of granulysin in macrophages, the expression of granulysin in the culture supernatants and cell lysates was verified by western blotting with rabbit anti-granulysin polyclonal antibody (Santa Cruz Biotechnology, Dallas, TX, USA; sc-28821) as a primary antibody and Peroxidase-conjugated Affinipure Goat Anti-Rabbit IgG(H+L) (Proteintech, Chicago, IL, USA; SA00001-2) as secondary antibody at 72 h post treatment.
At 0, 48 and 72 h after rAdhGLi treatment, cells were visualized by indirect immunofluorescence staining. Rabbit anti-granulysin polyclonal antibody was used as the primary antibody, and fluorescein (FITC)conjugated Affinipure Goat Anti-Rabbit IgG(H+L) (Proteintech, SA00003-2) was used as the secondary antibody. These stained cells were further re-stained with 4,6-Diamidino-2-phenylindole dihydrochloride for 5 min and imaged using an Olympus BX51 upright fluorescent microscope (Olympus, Tokyo, Japan).
The death and proliferation of rAdhGLi-treated U937 and RAW264.7 cells A total of 2 × 10 3 of U937 or RAW264.7 cells were plated in 96-well plates and infected with rAdhGLi as previously described. Proliferation of infected cells was analyzed using a Cell Counting Kit (Zoman Biotech, Beijing, China) 0, 24, 48, 72 and 96 h after rAdhGLi treatment. Culture medium and AdNull were used as negative controls. The OD 450nm value of each well was recorded by a plate reader, and the results are displayed as the mean OD 450nm ± s.d. of three repeats. Alternatively, 5 × 10 5 of both cells per well were plated in six-well plates and treated with rAdhGLi; 24, 48, 72 and 96 h after plating, apoptosis and necrosis of cells were determined using the Annexin V-APC/7-AAD kit (Keygen Biotech, Nanjing, China). Ten-thousand cells were collected from each sample and analyzed using a six color BD FACSCanto flow cytometer (BD Biosciences, San Jose, CA, USA). The results were analyzed by Flow Jo software (Tree Star Inc., Ashland, OR, USA) and are displayed as the mean ± s.d. of three repeats.
Ex vivo killing effect of rAdhGLi on intracellular M. tuberculosis
A total of 10 6 cells per well of U937 or RAW264.7 cells were plated on sixwell plates in triplicate wells and infected with M. tuberculosis H37Rv at a multiplicity of infection of 10:1 (bacteria: cells) for 24 h. The residual bacteria outside of the cells were removed by washing three times with sterilized PBS. Then, cells were treated with rAdhGLi at multiplicity of infection previously described for another 72 h. AdNull and culture medium were used as negative controls. After treatment, the number of existing M. tuberculosis in macrophages was qualitatively observed by AF staining and also quantitatively detected by bacterial CFU of the serial diluted solution with PBS on Middlebrook 7H11 agar (Difco Laboratories, Sparks, MD, USA) supplemented with 10% (v/v) ADC enrichment (Difco Laboratories) and 0.5% (v/v) glycerol. The results are displayed as the mean ± s.e.m. (log 10 CFU) of three repeats.
Expression and distribution of granulysin in rAdhGLi-treated BALB/c mice
Animal experiments were performed in accordance with the guidelines of the Chinese Council on Animal Care, and the research protocol was approved by the Tongji Medical School Committee on Biosafety (Wuhan, China). Specific pathogen-free female BALB/c mice 6 weeks of age (Vital River, Beijing, China) were treated with an i.n. rAdhGLi dosage of 10 7 PFU in 25 μl PBS. At 0, 24, 48, 72 h and 7 days after treatment, three mice in each group were killed, and the tissues were fixed by cardiac perfusion with 4% PBS-buffered paraformaldehyde. Organs including the lung, spleen, heart, liver and kidney were obtained for frozen sections. The expression of granulysin in these organs was detected by indirect immunofluorescence staining as previously described.
Therapeutic effects of rAdhGLi on M. tuberculosis-infected BALB/c mice To establish a mouse TB model, BALB/c mice were infected i.n. with virulent M. tuberculosis H37Rv. Three mice were killed the next day, and the lungs were removed from each mouse to determine the actual infection dose. Infected mice were grouped randomly, and five from each group were bred in separate cages in a biosafety laboratory and fed commercial mouse chow and water ad libitum. Two weeks later, mice were treated i.n. with serial doses of rAdhGLi, which consisted of 10 7 , 10 8 and 10 9 PFU in 25 μl PBS. Control mice were separately treated with PBS or 10 9 PFU of AdNull. Four weeks after treatment, mice were killed, and the bacterial load was analyzed by plating serial dilutions of lung homogenates onto 7H11 agar plates. The animal experiments were repeated twice, and the results were displayed as the mean ± s.e.m. (log 10 CFU) per lung. Left lung lobes from different groups were fixed in 10% PBS-buffered formalin, embedded in paraffin, sectioned and stained with hematoxylin and eosin and AF stain. The results of pathological changes were recorded by a pathologist with no prior knowledge of the treatment groups under a light microscope.
Therapeutic effects of rAdhGLi on M. tuberculosis-infected SCID mice Specific pathogen free female SCID mice aged 6-8 weeks (HFK Bioscience, Beijing, China) were infected i.n. with M. tuberculosis H37Rv as described above. Two weeks later, a dose of 10 9 PFU rAdhGLi in 25 μl PBS was given i.n. to mice. PBS and 10 9 PFU of AdNull were separately used as negative controls. Two weeks later, all mice were killed because control mice began to die. Bacterial load in both lungs and spleens (five mice per group) and lung histopathology were evaluated as previously described. The animal experiments were repeated twice.
Statistical analysis
Student's t test was used to compare the mean of each treatment, with a P-value of less than 0.05 considered statistically significant.
